Search Weight Loss Topics:

Aug 6

Ascendis Pharma A/S American (NASDAQ:ASND) Sees Light Trading Volume with 29K Shares Changing Hands – Modern Readers


29K shares changed hands in the last trading session. Trading volume was down 30.84% under the stocks average daily volume.

Here are a few other firms who have also updated their positions. As of quarter end Marshall Wace North America L.p. had sold a total of 5,001 shares trimming its holdings by 2.8%. The value of the total investment in Ascendis Pharma A/S American decreased from $5,022,000 to $4,882,000 a change of $140,000 since the last quarter. Alps Advisors Inc grew its investment by buying 2,144 shares an increase of 7.9% in the quarter. Alps Advisors Inc controls 29,264 shares worth $812,000. The value of the position overall is up by 7.0%.

Bank Of Montreal /can/ expanded its ownership by buying 2,541 shares an increase of 127.4% from 03/31/2017 to 06/30/2017. Bank Of Montreal /can/ now holds 4,535 shares with a value of $126,000. The total value of its holdings increased 125.0%. As of the end of the quarter Morgan Stanley had acquired 835 shares growing its position 126.1%. The value of the investment in (ASND) went from $13,000 to $42,000 a change of 223.1% quarter to quarter.

Equity analyst JP Morgan starting coverage on the stock giving it an initial rating of Overweight. On September 26 analysts at Wedbush released its first research report on the stock with an initial rating of Outperform and projecting a price target of $34.00.

Bank of America starting coverage on ASND setting a rating of Buy. On February 23, 2015 Wells Fargo added ASND to its research portfolio with a rating of Outperform.

On February 23 analysts at Leerink Swann issued its first research report on the stock by announcing an initial rating of Outperform and establishing a price target of $30.00.

The company is down by -0.04% since yesterdays close of $28.01.

Ascendis Pharma A/S, launched on September 21, 2006, is a clinical-stage biopharmaceutical company. The Company is involved in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. It is also using its TransCon technology platform to develop TransCon Parathyroid Hormone (TransCon PTH) for hypoparathyroidism, a rare endocrine disorder of calcium and phosphate metabolism. The Businesss subsidiaries include Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark) and Ascendis Pharma Growth Disorders A/S (Denmark)..

See more here:
Ascendis Pharma A/S American (NASDAQ:ASND) Sees Light Trading Volume with 29K Shares Changing Hands - Modern Readers

Related Post

Your Full Name
Your Email
Your Phone Number
Select your age (30+ only)
Select Your US State
Program Choice
Confirm over 30 years old Yes
Confirm that you resident in USA Yes
This is a Serious Inquiry Yes